相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease
Ruben J. Colman et al.
INFLAMMATORY BOWEL DISEASES (2021)
The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update
Patrick F. van Rheenen et al.
JOURNAL OF CROHNS & COLITIS (2021)
Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease
Laura E. Bauman et al.
INFLAMMATORY BOWEL DISEASES (2020)
Infliximab and its biosimilar produced similar first-year therapy outcomes in patients with inflammatory bowel disease
Anne Nikkonen et al.
ACTA PAEDIATRICA (2020)
Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Infliximab in Pediatric Inflammatory Bowel Disease: A Systematic Review and Revised Dosing Considerations
Dwight A. Winter et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2020)
Infliximab in young paediatric IBD patients: it is all about the dosing
Maria M. E. Jongsma et al.
EUROPEAN JOURNAL OF PEDIATRICS (2020)
Rapid weight gain in infliximab treated Crohn's disease patients is sustained over time: real-life data over 12 months
Johanna Lepp et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2020)
Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn's Disease in Children
Wael El-Matary et al.
INFLAMMATORY BOWEL DISEASES (2019)
Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD
Sara Lega et al.
INFLAMMATORY BOWEL DISEASES (2019)
Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN
Lissy de Ridder et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2019)
Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study
Samuele Naviglio et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2019)
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
So Yoon Choi et al.
GUT AND LIVER (2019)
Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients
Kathryn Clarkston et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2019)
A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
Martine A. Aardoom et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Management of Anti-drug Antibodies to Biologic Medications in Children With Inflammatory Bowel Disease
Reuven Zev Cohen et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2019)
Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease
Karen van Hoeve et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2019)
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases
Julien Kirchgesner et al.
GASTROENTEROLOGY (2018)
Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?
Xavier Roblin et al.
INFLAMMATORY BOWEL DISEASES (2018)
Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease
Tomer Greener et al.
INFLAMMATORY BOWEL DISEASES (2018)
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study
Luisa Guidi et al.
JOURNAL OF CROHNS & COLITIS (2018)
Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition
Dany Turner et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition
Dan Turner et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases
Bella Ungar et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease
Karen van Hoeve et al.
JOURNAL OF CROHNS & COLITIS (2018)
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy
H. Bar-Yoseph et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients
Marla C. Dubinsky et al.
AAPS JOURNAL (2017)
Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
Helena Rolandsdotter et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease
Laura Merras-Salmio et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2017)
Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease
Tatyana Hofmekler et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2017)
Biologic Agents Are Associated with Excessive Weight Gain in Children with Inflammatory Bowel Disease
Leonard Haas et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease
Vini Deora et al.
ACTA PAEDIATRICA (2017)
How effective is the use of long-term anti-TNF for paediatric IBD? Clues from real-life surveillance cohorts
Chani Topf-Olivestone et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease
Carlos Fernandes et al.
IMMUNOTHERAPY (2015)
The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease
Maria E. Joosse et al.
INFLAMMATORY BOWEL DISEASES (2015)
Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease
Taina Sipponen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar et al.
GUT (2014)
The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease
Kaija-Leena Kolho et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2014)
Pharmacokinetics of Infliximab in Children with Moderate-to-Severe Ulcerative Colitis: Results from a Randomized, Multicenter, Open-label, Phase 3 Study
Omoniyi J. Adedokun et al.
INFLAMMATORY BOWEL DISEASES (2013)
Serum infliximab concentrations in pediatric inflammatory bowel disease
Anssi Hamalainen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2013)
Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease
M. Chaparro et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents
Pauliina Molander et al.
INFLAMMATORY BOWEL DISEASES (2012)
The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited
C. I. de Bie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels
Anssi Hamalainen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
分享论文
